Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

BACKGROUND: The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monotherapy in reducing disease activity and signs and symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Gossec, Laure, Proudfoot, Clare W. J., Chen, Chieh-I, Reaney, Matthew, Guillonneau, Sophie, Kimura, Toshio, van Adelsberg, Janet, Lin, Yong, Mangan, Erin K., van Hoogstraten, Hubert, Burmester, Gerd R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009058/
https://www.ncbi.nlm.nih.gov/pubmed/29921318
http://dx.doi.org/10.1186/s13075-018-1614-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009058/
https://www.ncbi.nlm.nih.gov/pubmed/29921318
http://dx.doi.org/10.1186/s13075-018-1614-z

Ejemplares similares